New Biomarkers With Prognostic Impact Based on Multitracer PET/CT Imaging in Neuroendocrine Neoplasms: The Light Leading Out of the Darkness in Challenging Tumors.
Where this comes from
- Record sourced from PubMed, PMID 35067540.
- Also identified by DOI 10.1097/RLU.0000000000004062.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The search for new biomarkers in cancer is currently one of the most widely sought end points in medical imaging, with the aim of improving the management decisions based on reliable indicators of prognosis, being neuroendocrine neoplasms a challenging group of tumors under investigation. Multitracer PET/CT imaging, in which different radiotracers supply information of different metabolic aspects of the tumor, can help classify and select the most appropriate therapy, providing basic aspects that will probably allow the generation of new imaging biomarkers useful in patient management.
Medical subject headings
- Neuroendocrine Tumors
- Positron Emission Tomography Computed Tomography